Objectives: To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata). Design: Data from two international, double blind, placebo controlled, randomised efficacy trials of quadrivalent HPV vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)). The trials were to be 4 years in length, and the results reported are from final study data of 42 months' follow-up. Setting: Primary care centres and university or hospital associated health centres in 24 countries and territories around the world. Participants: 17 622 women aged 16-26 years enrolled between December 2001 and May 2003....
Background Human papillomavirus (HPV) vaccination protects against HPV, a necessary risk factor for ...
Objective: In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®) clinical program,...
The quadrivalent human papillomavirus (HPV) vaccine has been assumed to give protection against geni...
Objectives: To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vac...
Objectives: To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vac...
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on the risk of...
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/1...
SummaryBackgroundHuman papillomaviruses (HPVs) play an obligatory role in cervical cancer devel- opm...
Background: Vulval and vaginal cancers among younger women are often related to infection with human...
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, and...
Background Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-v...
Background A randomised double-blind placebo-controlled phase II study was done to assess the effica...
BACKGROUND: Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervic...
IEEE International Ultrasonics Symposium, IUS 201521 October 2015 through 24 October 2015118680Aim: ...
Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-partic...
Background Human papillomavirus (HPV) vaccination protects against HPV, a necessary risk factor for ...
Objective: In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®) clinical program,...
The quadrivalent human papillomavirus (HPV) vaccine has been assumed to give protection against geni...
Objectives: To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vac...
Objectives: To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vac...
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on the risk of...
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/1...
SummaryBackgroundHuman papillomaviruses (HPVs) play an obligatory role in cervical cancer devel- opm...
Background: Vulval and vaginal cancers among younger women are often related to infection with human...
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, and...
Background Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-v...
Background A randomised double-blind placebo-controlled phase II study was done to assess the effica...
BACKGROUND: Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervic...
IEEE International Ultrasonics Symposium, IUS 201521 October 2015 through 24 October 2015118680Aim: ...
Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-partic...
Background Human papillomavirus (HPV) vaccination protects against HPV, a necessary risk factor for ...
Objective: In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®) clinical program,...
The quadrivalent human papillomavirus (HPV) vaccine has been assumed to give protection against geni...